Core Insights - Zhongke Feimeasure (688361.SH) reported its Q3 2025 results, revealing that 135 institutional investors hold a total of 200 million shares, representing 62.10% of the company's total equity [1] - The top ten institutional investors collectively own 46.49% of the shares, with a slight decrease of 1.34 percentage points from the previous quarter [1] Institutional Holdings - In the latest period, 48 public funds increased their holdings, accounting for 3.96% of the total, with notable funds including Yongying Semiconductor Industry Selected Mixed Fund A and Huaxia SSE Sci-Tech Innovation Board Semiconductor Materials Equipment Theme ETF [2] - Conversely, 38 public funds reduced their holdings, representing a decrease of 1.38%, with significant funds like Yinhua Integrated Circuit Mixed Fund A and Harvest SSE Sci-Tech Innovation Board Chip ETF among them [2] - A total of 31 new public funds disclosed their holdings, including Kexin Semiconductor and Southern Changyuan Convertible Bond Fund A [2] - 428 public funds did not disclose their holdings in the current period, including Southern CSI 500 ETF and Guolian An Semiconductor ETF [2] Insurance Holdings - One insurance company, China Life Insurance Co., Ltd., reported a slight decrease in holdings, indicating a minor reduction in investment [2]

Core Insights - Zhongke Feimeasure experienced a slight decline of 0.18% on October 30, with a trading volume of 813 million yuan [1] - The company reported a net financing outflow of 28.22 million yuan on the same day, with a total financing and securities balance of 480 million yuan [1][2] - As of September 30, the company achieved a revenue of 1.202 billion yuan, marking a year-on-year growth of 47.92%, while the net profit attributable to shareholders was a loss of 14.6985 million yuan, an increase in loss of 71.67% year-on-year [2] Financing and Trading Activity - On October 30, Zhongke Feimeasure had a financing buy-in of 67.15 million yuan, with a current financing balance of 469 million yuan, representing 1.60% of the circulating market value [1] - The company’s financing balance is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - In terms of securities lending, the company repaid 27,800 shares and sold 1,100 shares on October 30, with a total selling amount of approximately 129,800 yuan [1] Shareholder and Institutional Holdings - As of September 30, the number of shareholders for Zhongke Feimeasure increased by 40.11% to 13,700, while the average circulating shares per person decreased by 28.63% to 18,131 shares [2] - The company has distributed a total of 44.8 million yuan in dividends since its A-share listing [3] - Notable institutional shareholders include Noan Growth Mixed A, holding 13.4533 million shares, and Yongying Semiconductor Industry Mixed Fund A, which is a new shareholder with 6 million shares [3]

Core Viewpoint - Zhongke Feicai, a leading manufacturer of integrated circuit testing equipment in China, was established on December 31, 2014, and went public on May 19, 2023, on the Shanghai Stock Exchange, breaking the long-standing monopoly of foreign manufacturers in the industry [1] Group 1: Business Performance - In Q3 2025, Zhongke Feicai reported revenue of 1.202 billion yuan, ranking 11th among 22 companies in the industry, with the industry leader, North Huachuang, generating 27.301 billion yuan [2] - The revenue composition includes 426 million yuan from testing equipment (60.72%), 256 million yuan from measurement equipment (36.40%), and 2.0378 million yuan from services and others (2.88%) [2] - The net profit for the same period was -14.6985 million yuan, placing the company 20th in the industry, while the industry leader reported a net profit of 4.98 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Zhongke Feicai's debt-to-asset ratio was 51.02%, higher than the industry average of 35.23% [3] - The gross profit margin for Q3 2025 was 51.97%, exceeding the industry average of 38.42% [3] Group 3: Executive Compensation - Chairman Chen Lu's compensation increased from 4.0817 million yuan in 2023 to 5.2858 million yuan in 2024, an increase of 1.2041 million yuan [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 40.11% to 13,700, with an average holding of 18,100 circulating A-shares, a decrease of 28.63% [5] Group 5: Growth and Projections - In H1 2025, Zhongke Feicai's revenue was 702 million yuan, a year-on-year increase of 51.39%, with a net profit of -18 million yuan, showing a significant reduction in losses [6][7] - The company expects revenues of 1.916 billion yuan, 2.680 billion yuan, and 3.444 billion yuan for 2025, 2026, and 2027, respectively, with corresponding net profits projected at 219 million yuan, 391 million yuan, and 594 million yuan [7]

Group 1 - The core point of the article is that Zhongke Feice announced a financial impairment test and recognized impairment losses for the period ending September 30, 2025, amounting to RMB 67,685,241.42 [2] Group 2 - The company conducted impairment testing on assets within the consolidation scope that showed signs of impairment [2] - The recognized credit impairment losses and asset impairment losses for the period from January to September 2025 totaled RMB 67,685,241.42 [2]

Core Viewpoint - Shenzhen Zhongke Feimeasure Technology Co., Ltd. announced the approval of using self-owned funds and bank credit funds to pay for part of the fundraising projects, with plans to later replace these with the raised funds, aiming to improve fund utilization efficiency and ensure smooth project advancement [1][5]. Fundraising Basic Situation - The company completed a private placement of A-shares on August 2025, issuing 28.571428 million shares at a price of 87.50 yuan per share, raising a total of 2.5 billion yuan. After deducting issuance costs of 19.2326 million yuan (excluding VAT), the actual net fundraising amount was 2.4807674 billion yuan, which has been deposited in a special account for raised funds [2]. Fund Allocation After Adjustment - The net fundraising will be allocated to four major projects, with adjustments made to the amounts for some projects. The details are as follows: 1. Shanghai High-end Semiconductor Quality Control Equipment Industrialization Project: Total investment 845.7298 million yuan, adjusted amount 714.7674 million yuan 2. Shanghai High-end Semiconductor Quality Control Equipment R&D Testing Center Project: Total investment 635.1633 million yuan, adjusted amount 446 million yuan 3. Headquarters Base and R&D Center Upgrade Project: Total investment 670.9743 million yuan, adjusted amount 620 million yuan 4. Supplementing Working Capital: Total investment 700 million yuan, unchanged at 700 million yuan - Total investment: 2.8518674 billion yuan, adjusted total amount: 2.4807674 billion yuan [3]. Reasons and Process for Replacement - The company stated that the use of self-owned and bank credit funds for initial payments is based on three reasons: 1. Employee salaries and social security payments must be made from basic deposit accounts, not directly from the special fundraising account 2. To improve fund utilization efficiency and reduce financial costs, allowing for flexible payment methods 3. For equipment or raw material purchases involving foreign exchange settlements, self-owned funds are required for initial payments [3]. Operational Process - The company will execute the process in four steps: 1. Project management department submits payment requests and follows approval procedures 2. Finance department establishes a payment detail ledger and summarizes payment status monthly 3. Monthly initiation of fundraising replacement applications, with funds transferred from the special account to the self-owned account after approval 4. The sponsor conducts supervision through on-site inspections and written inquiries [4]. No Adverse Impact on Operations - Zhongke Feimeasure emphasized that this operation complies with regulations and will not affect the normal implementation of fundraising projects. The board and supervisory board have approved the proposal without needing to submit it to the shareholders' meeting. The supervisory board noted that this matter is beneficial for improving fundraising efficiency and aligns with the overall interests of the company and shareholders [5].

证券代码：688361 证券简称：中科飞测 公告编号：2025-061 关于 2025 年前三季度计提资产减值准备的公告 二、 计提减值准备事项的具体说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 计提减值准备的情况概述 深圳中科飞测科技股份有限公司（以下简称"公司"）根据《企业会计准则 第 8 号——资产减值》《企业会计准则第 22 号——金融工具确认和计量》（以下 合称"《企业会计准则》"）和相关会计政策的规定，结合公司的实际情况，为 客观、公允地反映公司截至 2025 年 9 月 30 日的财务状况和 2025 年 1-9 月的经 营成果，公司对截至 2025 年 9 月 30 日合并范围内存在减值迹象的资产进行了减 值测试并计提了相应的减值准备，2025 年 1-9 月公司确认的计提信用减值损失及 资产减值损失共计人民币 67,685,241.42 元，具体情况如下： 单位：人民币元 （一） 信用减值损失 | 项目 | 2025 年 | 1-9 | 月计提金额 | 备注 | | --- | --- | ...

深圳中科飞测科技股份有限公司 募投项目通过公司的子公司或公司控制的其他企业实施的，公司应 当确保该子公司或控制的其他企业遵守本办法。 第六条 募集资金的使用坚持周密计划、规范运作和公开透明的原则。非经 公司股东会依法作出决议，任何人无权改变公司公开披露的募集资 金用途。 募集资金管理和使用办法 第一章 总 则 公司控股股东、实际控制人不得直接或者间接占用或者挪用公司募 1 第一条 为规范深圳中科飞测科技股份有限公司（以下简称"公司"）在中 国境内（为本办法之目的，不包括香港特别行政区、澳门特别行政 区和台湾省）募集资金的管理和使用，提高募集资金使用效率，维 护全体股东的合法权益，依据《中华人民共和国公司法》《中华人 民共和国证券法》《上海证券交易所科创板上市公司自律监管指引 第 1 号—规范运作》《上市公司募集资金监管规则》等有关法律、 法规、规范性文件及《深圳中科飞测科技股份有限公司章程》（以 下简称"《公司章程》"）等公司规章制度，并结合公司实际情况， 制定本《深圳中科飞测科技股份有限公司募集资金管理和使用办法》 （以下简称"本办法"）。 第二条 本办法所称募集资金是指公司通过在中国境内公开发行证券（包括 ...

证券代码：688361 证券简称：中科飞测 公告编号：2025-058 深圳中科飞测科技股份有限公司 关于使用自有资金、银行信贷资金等 支付募投项目部分款项并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳中科飞测科技股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日分别召开了第二届董事会第十七次会议和第二届监事会第十五次会议，审议通 过了《关于使用自有资金、银行信贷资金等支付募投项目部分款项并以募集资金 等额置换的议案》，同意公司在募集资金投资项目（以下简称"募投项目"）实 施期间，使用自有资金、银行信贷资金等支付募投项目部分款项并以募集资金等 额置换，并明确了上述等额置换的具体操作流程规范。公司监事会对以上事项发 表了明确同意的意见，保荐人国泰海通证券股份有限公司（以下简称"保荐人"） 对此出具明确的核查意见。现将具体情况公告如下： 一、 募集资金基本情况 根据中国证券监督管理委员会于 2025 年 8 月 4 日出具的《关于同意深圳中 科飞测科技股份有限公司向特定对象发 ...

证券代码：688361 证券简称：中科飞测 公告编号：2025-059 公司监事会对以上事项发表了明确同意的意见，保荐人国泰海通证券股份有 限公司（以下简称"保荐人"）对此出具无异议的核查意见。 一、 募集资金基本情况 据中国证券监督管理委员会于 2025 年 8 月 4 日出具的《关于同意深圳中科 飞测科技股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕1640 号），公司 2024 年度向特定对象发行 A 股股票 28,571,428 股，发行价格 87.50 元/股，募集资金总额为人民币 250,000.00 万元，扣除各项发行费用（不含增值 税）人民币 1,923.26 万元后，实际募集资金净额为人民币 248,076.74 万元。上述 募集资金到位情况已经容诚会计师事务所（特殊普通合伙）审验，并出具容诚验 深圳中科飞测科技股份有限公司 关于使用部分募集资金向全资子公司提供借款 以实施募投项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳中科飞测科技股份有限公司（以下简称"公司"）于 ...

证券代码：688361 证券简称：中科飞测 公告编号：2025-054 深圳中科飞测科技股份有限公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司董事会对应佳先生在担任公司保荐代表人期间所做出的贡献表示衷心 的感谢！ 特此公告。 深圳中科飞测科技股份有限公司董事会 2025 年 10 月 31 日 附件：保荐代表人谢欣灵 谢欣灵先生，国泰海通证券股份有限公司投资银行部执行董事，上海交通大 学硕士研究生，保荐代表人、加拿大特许专业会计师，曾负责或参与晶晨股 份、源杰科技、中科飞测、华虹公司、新芯股份、长光辰芯、北京君正等 IPO 项目，本钢板材、北京君正、中科飞测等再融资项目，融和租赁等公司债项 目。谢欣灵先生在保荐业务执业过程中严格遵守《证券发行上市保荐业务管 理办法》等有关规定，执业记录良好。 深圳中科飞测科技股份有限公司（以下简称"公司"）于近日收到公司保荐 人国泰海通证券股份有限公司（以下简称"国泰海通"）出具的《关于更换深圳 中科飞测科技股份有限公司持续督导保荐代表人的函》 ...